## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.2% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 3)

**1. Muscles, the New Flex: Abbott Launches Two New EnsureÂ® Max Protein Shakes to Tap into Growing Muscle Health Movement**
- Source: PR Newswire | 20251204T160734 | Bullish | Relevance: 100%
- Abbott has launched two new Ensure Max Protein shakes to address the growing muscle health movement, especially for adults over 40. The Ensure Max Protein 42g is designed for physically active adults, providing 42 grams of protein, while the Ensure Max Protein 2 in 1 Muscle Support is for older adults, offering 30 grams of protein and CaHMB to help preserve muscle. Former professional quarterback Matt Ryan is collaborating with Abbott to raise awareness about the importance of muscle health.

**2. Don't Ignore The Insider Selling In Abbott Laboratories**
- Source: Simply Wall Street | 20251204T110747 | Somewhat-Bearish | Relevance: 100%
- An insider at Abbott Laboratories recently sold US$203k worth of shares, though this represented only a 5.0% reduction in their total holdings. This follows a larger sale by the CFO & Executive VP of Finance for US$747k in the last 12 months, both transactions occurring around the current share price. While insider selling can be concerning, the company has high insider ownership and growing profits, despite the recent sales.

**3. Muscles, the New Flex: Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement**
- Source: Finviz | 20251204T110000 | Bullish | Relevance: 100%
- Abbott (NYSE: ABT) has launched two new Ensure Max Protein shakes, Ensure Max Protein 42g and Ensure Max Protein 2 in 1 Muscle Support, to address muscle health, particularly for adults over 40 who can lose significant muscle mass. Former NFL MVP Matt Ryan is partnering with Abbott to raise awareness about the importance of muscle health. The products are designed for active adults and older adults, with the latter containing CaHMB to help slow muscle breakdown, and are exclusively available at Walmart until March 2026.

**4. Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups**
- Source: USA Herald | 20251203T185140 | Bearish | Relevance: 100%
- Seven states have joined a False Claims Act lawsuit against Abbott Laboratories, accusing the company of knowingly endangering infants and misrepresenting safety compliance related to federally funded nutrition programs. The 176-page intervention alleges that Abbott's Sturgis plant had endemic contamination and that the company concealed violations to secure formula contracts, affecting millions of vulnerable infants reliant on Medicaid and WIC programs. This legal escalation stems from the 2022 infant formula crisis and highlights the alleged misconduct's impact on public health and taxpayer-funded programs.

**5. Abbott Laboratories (NYSE: ABT) sees Vanguard report 10.05% beneficial stake**
- Source: Stock Titan | 20251203T110200 | Neutral | Relevance: 100%
- The Vanguard Group has disclosed an updated beneficial ownership stake of 10.05% in Abbott Laboratories (NYSE: ABT), holding 174,894,079 common shares. This Schedule 13G/A filing indicates that Vanguard, acting as an investment adviser, holds these securities in the ordinary course of business, not for influencing control of Abbott. The report details Vanguard's voting and dispositive powers, clarifying that clients receive dividends and sale proceeds.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.3B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.1 |
| Current P/E | 24.2 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.1% to -3.2% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 43. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.20% (CS: 18) | Weak |
| RSI_14 | 43.0 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.958x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.40
- **Stop Loss:** $120.28 (4.1% risk)
- **Target:** $130.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 97
- **Position Value:** $12,163.80
- **Portfolio %:** 12.16%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*